Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.65 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639220 | 0.92 | AR (0.62) | ARSRD5A1SRD5A2LMNAKCNH2 | |
| SCHEMBL4801200 | 0.92 | AR (0.62) | ARSRD5A1SRD5A2LMNAKCNH2 | |
| SCHEMBL4801209 | 0.92 | AR (0.62) | ARSRD5A1SRD5A2LMNAKCNH2 | |
| SCHEMBL14223747 | 0.91 | AR (0.57) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL2641287 | 0.90 | AR (0.56) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL4799711 | 0.90 | AR (0.56) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL4799705 | 0.90 | AR (0.56) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL14184876 | 0.90 | AR (0.77) | ARSRD5A1SRD5A2KCNH2 | |
| SCHEMBL2641215 | 0.90 | AR (0.77) | ARSRD5A1SRD5A2KCNH2 | |
| SCHEMBL4801324 | 0.88 | AR (0.58) | ARSRD5A1SRD5A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622567-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | claimed |
| JP-4832303-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1622567-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | claimed |
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME LLC | 2006-10-26 | — | — | US | claimed |
| EP-1622567-A2 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| WO-2004100874-A2 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2004-11-25 | — | — | WO | claimed |
| EP-1622567-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-7351698-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME LLC | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | AR 3/4885SRD5A1 42/4885SRD5A2 57/4885 |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | AR 3/4885SRD5A1 42/4885SRD5A2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.